292 related articles for article (PubMed ID: 26976868)
1. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
[TBL] [Abstract][Full Text] [Related]
2. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
4. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability.
Kwon YS; Jeong BH; Koh WJ
Expert Opin Pharmacother; 2015 Feb; 16(2):253-61. PubMed ID: 25327169
[TBL] [Abstract][Full Text] [Related]
5. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.
Wen S; Jing W; Zhang T; Zong Z; Xue Y; Shang Y; Wang F; Huang H; Chu N; Pang Y
Eur J Clin Microbiol Infect Dis; 2019 Jul; 38(7):1293-1296. PubMed ID: 30953211
[TBL] [Abstract][Full Text] [Related]
6. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
[TBL] [Abstract][Full Text] [Related]
7. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system.
Schena E; Nedialkova L; Borroni E; Battaglia S; Cabibbe AM; Niemann S; Utpatel C; Merker M; Trovato A; Hofmann-Thiel S; Hoffmann H; Cirillo DM
J Antimicrob Chemother; 2016 Jun; 71(6):1532-9. PubMed ID: 27076101
[TBL] [Abstract][Full Text] [Related]
8. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
9.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
10. Delamanid Kills Dormant Mycobacteria
Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
[TBL] [Abstract][Full Text] [Related]
11. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis.
Rancoita PMV; Cugnata F; Gibertoni Cruz AL; Borroni E; Hoosdally SJ; Walker TM; Grazian C; Davies TJ; Peto TEA; Crook DW; Fowler PW; Cirillo DM;
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941636
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis.
Fujiwara M; Kawasaki M; Hariguchi N; Liu Y; Matsumoto M
Tuberculosis (Edinb); 2018 Jan; 108():186-194. PubMed ID: 29523322
[TBL] [Abstract][Full Text] [Related]
13. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis.
Blair HA; Scott LJ
Drugs; 2015 Jan; 75(1):91-100. PubMed ID: 25404020
[TBL] [Abstract][Full Text] [Related]
14. Delamanid: first global approval.
Ryan NJ; Lo JH
Drugs; 2014 Jun; 74(9):1041-5. PubMed ID: 24923253
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates.
Zhang Z; Li T; Qu G; Pang Y; Zhao Y
Int J Antimicrob Agents; 2015 Jan; 45(1):71-5. PubMed ID: 25459737
[TBL] [Abstract][Full Text] [Related]
16. Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent.
Luo W; Huang Z; Xu D; Yang M; Zhu Y; Shen L; Chen S; Tao X; Bin W; Hu Y; Franzblau SG; Jiang N; Wei Y; Wei X; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 72():128871. PubMed ID: 35777718
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid.
Van den Bossche A; Varet H; Sury A; Sismeiro O; Legendre R; Coppee JY; Mathys V; Ceyssens PJ
Tuberculosis (Edinb); 2019 Jul; 117():18-23. PubMed ID: 31378263
[TBL] [Abstract][Full Text] [Related]
18. Profile of delamanid for the treatment of multidrug-resistant tuberculosis.
Szumowski JD; Lynch JB
Drug Des Devel Ther; 2015; 9():677-82. PubMed ID: 25678771
[TBL] [Abstract][Full Text] [Related]
19. Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.
Mandal A; Parthasarathy G; Burma SP; Sugunan AP; Vijayachari P
Indian J Tuberc; 2015 Jan; 62(1):23-8. PubMed ID: 25857562
[TBL] [Abstract][Full Text] [Related]
20. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients.
Diacon AH; Dawson R; Hanekom M; Narunsky K; Venter A; Hittel N; Geiter LJ; Wells CD; Paccaly AJ; Donald PR
Int J Tuberc Lung Dis; 2011 Jul; 15(7):949-54. PubMed ID: 21682970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
